Neogen Chemicals (NEOGEN) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
10 Nov, 2025Executive summary
Q2 FY 2026 saw 8% revenue growth and 16% gross profit improvement, despite operational disruptions from a Dahej plant outage, which was mitigated by shifting production and outsourcing, incurring temporary costs.
Strategic milestones included the formation of an Indo-Japan JV for battery materials, key customer approvals for electrolyte and salt, and enhanced corporate governance with board role separation.
Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with limited review by statutory auditors and no material misstatements identified.
Amalgamation of Buli Chemicals India Private Limited completed, with retrospective restatement of prior periods.
Financial highlights
Q2 FY 2026 consolidated revenue was INR 209 crore, up 8% year-over-year; organic revenue grew 12% to INR 184 crore, inorganic revenue was INR 24 crore.
Neogen Ionics contributed INR 5.42 crore to revenue; EBITDA was INR 30 crore, with margin pressure from higher employee costs, insurance premiums, and outsourcing.
PAT for Q2 FY 2026 was INR 3 crore, impacted by increased operational and finance costs, and lower Dahej plant utilization.
Standalone revenue for Q2 FY26 was INR 206.7 crore; standalone PAT was INR 9.3 crore.
Standalone EBITDA margin for H1 FY26: 17%; consolidated EBITDA margin for H1 FY26: 14%.
Outlook and guidance
Battery Chemicals revenue guidance for FY 2026 revised down to INR 30–40 crore due to delayed customer ramp-up; FY 2027 guidance is INR 400–500 crore, with full utilization targeted by FY 2029 (INR 2,400–2,900 crore).
Base business revenue on track for INR 850 crore in FY 2026 and INR 950–1,000 crore in FY 2027, with double-digit growth targeted for FY 2028 without major CapEx.
Margin guidance for standalone business is 18% ±1–1.5% at full utilization; Neogen Ionics targets 20% ROC, with EBITDA margin for battery business expected at 16–20% depending on lithium prices.
Significant ramp-up in battery materials expected next year as new projects commission and Dahej plant rebuild completes.
Latest events from Neogen Chemicals
- Q3 FY26 revenue up 9% YoY; battery chemical expansion and equity fundraising advance.NEOGEN
Q3 25/2612 Feb 2026 - FY25 revenue up 13%, fire loss offset by insurance, and battery materials expansion underway.NEOGEN
Q4 24/253 Feb 2026 - Q1 FY25 profit and revenue rose 9% and 18%, with battery chemical expansion and board changes.NEOGEN
Q1 24/252 Feb 2026 - Q2 FY25 delivered 20% revenue and 38% PAT growth, with robust expansion and global focus.NEOGEN
Q2 24/2514 Jan 2026 - Q3 FY25 delivered 22% revenue and 844% PAT growth, led by BuLi Chem and battery materials.NEOGEN
Q3 24/259 Jan 2026 - Q1 FY26 delivered resilient growth, CapEx progress, and leadership transition amid recovery.NEOGEN
Q1 25/2623 Nov 2025